OGM & FDA: The Saga Continues The FDA’s shift
Post# of 56
(Total Views: 50)
Posted On: 05/19/2025 7:48:26 AM
OGM & FDA: The Saga Continues
The FDA’s shift toward AI-based computational models for drug testing could pave the way for optical genome mapping (OGM) to gain regulatory approval. The agency is phasing out animal testing in favor of human-relevant methods, including AI-driven toxicity models, organ-on-a-chip systems, and computational simulations.
While the FDA has not yet issued specific guidance on OGM, its focus on advanced genomic tools suggests that technologies like OGM could be fast-tracked for validation in clinical diagnostics and drug development.
The FDA’s shift toward AI-based computational models for drug testing could pave the way for optical genome mapping (OGM) to gain regulatory approval. The agency is phasing out animal testing in favor of human-relevant methods, including AI-driven toxicity models, organ-on-a-chip systems, and computational simulations.
While the FDA has not yet issued specific guidance on OGM, its focus on advanced genomic tools suggests that technologies like OGM could be fast-tracked for validation in clinical diagnostics and drug development.
(0)
(0)Bionano Genomics Inc. (BNGO) Stock Research Links
Scroll down for more posts ▼